A Nicotinamide Phosphoribosyltransferase Inhibitor, FK866, Suppresses the Growth of Anaplastic Meningiomas and Inhibits Immune Checkpoint Expression by Regulating STAT1
Anaplastic meningioma is classified as a World Health Organization (WHO) grade III tumor and shows a strong tendency to recur. Although the incidence of anaplastic meningioma is low, the high rate of recurrence and death still makes treatment a challenge. A proteomics analysis was performed to inves...
Main Authors: | Yuxuan Deng, Boyi Hu, Yazhou Miao, Jing Wang, Shaodong Zhang, Hong Wan, Zhen Wu, Yifan Lv, Jie Feng, Nan Ji, Deric Park, Shuyu Hao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.836257/full |
Similar Items
-
Extracellular Nicotinamide Phosphoribosyltransferase Is a Component of the Senescence-Associated Secretory Phenotype
by: Chisaka Kuehnemann, et al.
Published: (2022-07-01) -
The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells
by: Maxime Parisotto, et al.
Published: (2022-11-01) -
The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth
by: Kishor Pant, et al.
Published: (2023-02-01) -
Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors
by: Sadrerafi K, et al.
Published: (2018-04-01) -
Extracellular nicotinamide phosphoribosyltransferase: role in disease pathophysiology and as a biomarker
by: Elise Semerena, et al.
Published: (2023-10-01)